(19)
(11) EP 3 448 852 A1

(12)

(43) Date of publication:
06.03.2019 Bulletin 2019/10

(21) Application number: 17788800.5

(22) Date of filing: 27.04.2017
(51) International Patent Classification (IPC): 
C07D 401/14(2006.01)
C07D 401/04(2006.01)
C07D 403/14(2006.01)
C07D 487/04(2006.01)
C07D 491/10(2006.01)
A61K 31/4439(2006.01)
 C07D 401/10(2006.01)
C07D 403/10(2006.01)
C07D 471/04(2006.01)
C07D 487/10(2006.01)
C07D 498/08(2006.01)
(86) International application number:
PCT/CN2017/082243
(87) International publication number:
WO 2017/186148 (02.11.2017 Gazette 2017/44)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

(30) Priority: 29.04.2016 US 201662391402 P

(71) Applicant: Astar Biotech LLC
Richmond, VA 23219 (US)

(72) Inventors:
  • LI, Lianhai
    Pierrefonds Québec H9H 2V6 (CA)
  • YU, Chunrong
    Glen Allen VA 23060 (US)
  • HUANG, Haihong
    Beijing 100050 (CN)

(74) Representative: Grünecker Patent- und Rechtsanwälte PartG mbB 
Leopoldstraße 4
80802 München
80802 München (DE)

   


(54) NOVEL HETEROCYCLIC COMPOUNDS AS TYROSINE KINASE BCR-ABL INHIBITORS